Desmarets J, Frelin C
Institut de Pharmacologie Moléculaire et Cellulaire, CNRS UPR 411, 660 route des Lucioles, Valbonne, 06560, France.
Biochem Biophys Res Commun. 1999 Mar 16;256(2):357-60. doi: 10.1006/bbrc.1999.0331.
Pharmacological evidence has suggested that endothelin-3 (ET-3) may act via a novel form of ET receptor that is shared by ETA receptor antagonists but not by ETB receptor selective agonists. This study analyses the properties of interaction of ET-3 with recombinant bovine ETA receptor. Apparent Kd(ET-3) values as low as 50 nM were defined from [125I]ET-1 binding experiments performed at low (5 microg/ml) protein concentrations in the assays. Larger (up to 1 microM) values were artefactually obtained in experiments performed at larger protein concentrations. The three monoiodo ET-3 derivatives were synthetized. ([125I]Y14)ET-3 did not recognize ETA receptors. ([125I]Y6)ET-3 labelled 18% of [125I]ET-1 binding sites with a Kd value of 320 pM. ([125I]Y13)ET-3 labelled 44% of [125I]ET-1 binding sites with a Kd value of 130 pM. High affinity ([125I]Y6)ET-3 and ([125I]Y13)ET-3 bindings were prevented by ET-1 (Kd = 5-7 pM), ET-3 (Kd = 70-250 pM), BQ-123 (Kd = 2 nM) and FR139317 (Kd = 2 nM) but not by low concentrations of 4-AlaET-1, sarafotoxin S6c or IRL1620. The three monoiodo ET-3 derivatives bound to recombinant rat ETB receptors with a pM affinity. The results suggest that ET-3, ([125I]Y6)ET-3 and ([125I]Y13)ET-3 should not be considered as ETB receptor specific ligands.
药理学证据表明,内皮素-3(ET-3)可能通过一种新型的ET受体发挥作用,这种受体可被ETA受体拮抗剂识别,但不能被ETB受体选择性激动剂识别。本研究分析了ET-3与重组牛ETA受体的相互作用特性。在低蛋白浓度(5微克/毫升)的实验中,通过[125I]ET-1结合实验确定的表观Kd(ET-3)值低至50纳摩尔。在较高蛋白浓度下进行的实验中,会人为获得较大(高达1微摩尔)的值。合成了三种单碘ET-3衍生物。([125I]Y14)ET-3不能识别ETA受体。([125I]Y6)ET-3标记了18%的[125I]ET-1结合位点,Kd值为320皮摩尔。([125I]Y13)ET-3标记了44%的[125I]ET-1结合位点,Kd值为130皮摩尔。ET-1(Kd = 5 - 7皮摩尔)、ET-3(Kd = 70 - 250皮摩尔)、BQ-123(Kd = 2纳摩尔)和FR139317(Kd = 2纳摩尔)可抑制高亲和力的([125I]Y6)ET-3和([125I]Y13)ET-3结合,但低浓度的4-丙氨酸ET-1、毒蜘蛛毒素S6c或IRL1620则不能。这三种单碘ET-3衍生物以皮摩尔亲和力与重组大鼠ETB受体结合。结果表明,ET-3、([125I]Y6)ET-3和([125I]Y13)ET-3不应被视为ETB受体特异性配体。